.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Fish and Richardson
Baxter
Covington
Novartis
Chubb
US Army
Johnson and Johnson
Fuji
Cerilliant

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205879

« Back to Dashboard
NDA 205879 describes INVOKAMET XR, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the INVOKAMET XR profile page.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

Summary for NDA: 205879

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 205879

Suppliers and Packaging for NDA: 205879

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL 205879 NDA Janssen Pharmaceuticals, Inc. 50458-940 50458-940-01 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-940-01)
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL 205879 NDA Janssen Pharmaceuticals, Inc. 50458-941 50458-941-01 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (50458-941-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength50MG;500MG
Approval Date:Sep 20, 2016TE:RLD:Yes
Patent:6,723,340Patent Expiration:Oct 25, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:7,943,788Patent Expiration:Jul 14, 2027Product Flag?YSubstance Flag?YDelist Request?
Patent:8,785,403Patent Expiration:Jul 30, 2024Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Chinese Patent Office
Express Scripts
Dow
Healthtrust
Fuji
Covington
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot